Literature DB >> 7986270

Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53.

K A Howes1, N Ransom, D S Papermaster, J G Lasudry, D M Albert, J J Windle.   

Abstract

A transgenic mouse model for retinoblastoma was produced previously by directing SV40 T antigen expression to retinal photoreceptor cells using the promoter of the interstitial retinol-binding protein (IRBP) gene. This gene becomes active prior to the terminal differentiation of photoreceptors. Because T antigen-transforming activity is attributable, at least in part, to the inactivation of the retinoblastoma (pRb) and p53 tumor suppressor proteins, we addressed the role of p53 in the development of retinoblastoma in mice. Transgenic mice expressing HPV-16 E7 under the control of the IRBP promoter were generated to inactivate pRb in photoreceptors while leaving p53 intact. Rather than developing retinoblastomas, the retinas of these mice degenerate due to photoreceptor cell death at a time in development when photoreceptors are normally undergoing terminal differentiation. The dying cells exhibit the histological and ultrastructural features of apoptosis and contain fragmented DNA. p53 is required for the induction of apoptosis in this model, because mice expressing E7 in a p53 nullizygous background develop retinal tumors instead of undergoing retinal degeneration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986270     DOI: 10.1101/gad.8.11.1300

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  71 in total

Review 1.  Using mice to examine p53 functions in cancer, aging, and longevity.

Authors:  Lawrence A Donehower
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-11-04       Impact factor: 10.005

Review 2.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

3.  Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3.

Authors:  B Mannhardt; S A Weinzimer; M Wagner; M Fiedler; P Cohen; P Jansen-Dürr; W Zwerschke
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

4.  Both conserved region 1 (CR1) and CR2 of the human papillomavirus type 16 E7 oncogene are required for induction of epidermal hyperplasia and tumor formation in transgenic mice.

Authors:  G A Gulliver; R L Herber; A Liem; P F Lambert
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 5.  Mechanisms of human papillomavirus-induced oncogenesis.

Authors:  Karl Münger; Amy Baldwin; Kirsten M Edwards; Hiroyuki Hayakawa; Christine L Nguyen; Michael Owens; Miranda Grace; Kyungwon Huh
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Blimp1 suppresses Chx10 expression in differentiating retinal photoreceptor precursors to ensure proper photoreceptor development.

Authors:  Kimiko Katoh; Yoshihiro Omori; Akishi Onishi; Shigeru Sato; Mineo Kondo; Takahisa Furukawa
Journal:  J Neurosci       Date:  2010-05-12       Impact factor: 6.167

Review 7.  Eye cancer: unique insights into oncogenesis: the Cogan Lecture.

Authors:  J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

8.  Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines.

Authors:  W Li; J Fan; D Hochhauser; D Banerjee; Z Zielinski; A Almasan; Y Yin; R Kelly; G M Wahl; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

9.  Functional interaction between DP-1 and p53.

Authors:  T S Sørensen; R Girling; C W Lee; J Gannon; L R Bandara; N B La Thangue
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

Review 10.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.